Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Additional treatment for improving severe colitis
ISRCTN17100156Phase 3Recruiting
- Sponsor
- Hull University Teaching Hospitals
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Upadacitinib + standard care with Placebo + standard care (2 arms). Primary endpoint: Need for rescue therapy within 10 days. Started Apr 2025; status: recruiting.
02
Drugs
upadacitinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on ISRCTN17100156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17100156.